1h Free Analyst Time
According to the recently published report 'Histone Deacetylase 6 - Drugs In Development, 2022'; Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 53 molecules. Out of which approximately 44 molecules are developed by companies and remaining by the universities/institutes.Speak directly to the analyst to clarify any post sales queries you may have.
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.
The report 'Histone Deacetylase 6 - Drugs In Development, 2022' outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 4, 1, 27 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Toxicology, Respiratory, Cardiovascular, Gastrointestinal, Infectious Disease, Musculoskeletal Disorders and Undisclosed which include indications Multiple Myeloma (Kahler Disease), Melanoma, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Breast Cancer, Charcot-Marie-Tooth Disease Type II, Charcot-Marie-Tooth Disease, Chemotherapy Induced Peripheral Neuropathy, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Multiple Sclerosis, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Triple-Negative Breast Cancer (TNBC), Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Follicular Lymphoma, Idiopathic Pulmonary Fibrosis, Leukemia, Mantle Cell Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rheumatoid Arthritis, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Anal Cancer, Anaplastic Astrocytoma, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Burkitt Lymphoma, Cervical Cancer, Charcot-Marie-Tooth Disease Type I A, CNS Lymphoma, Crohn's Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Diastolic Heart Failure, Dilated Cardiomyopathy, Distal Symmetric Polyneuropathy, Fibrosis, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Liver Cancer, Lung Adenocarcinoma, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Melanoma, Mycosis Fungoides, Myelodysplastic Syndrome, Myeloproliferative Disorders, Neuroblastoma, Neuroendocrine Tumors, Neurology, Neuropathic Pain (Neuralgia), Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Polycystic Kidney Disease, Rectal Cancer, Recurrent Medulloblastoma, Rett Syndrome, Sepsis, Small-Cell Lung Cancer, Systemic Sclerosis (Scleroderma), Tauopathies, Ulcerative Colitis, Unspecified, Unspecified B-Cell Lymphomas, Unspecified Cancer and Vulvar Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Overview
- Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
- Annji Pharmaceutical Co Ltd
- ATP Biopharm
- Augustine Therapeutics
- Avstera Therapeutics Inc
- Beijing Konruns Pharmaceutical Co Ltd
- Bristol-Myers Squibb Co
- Chong Kun Dang Pharmaceutical Corporation
- Convalife
- CStone Pharmaceuticals Co Ltd
- Curis Inc
- Eikonizo Therapeutics Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Hillstream BioPharma Inc
- Jubilant Therapeutics Inc
- Kancera AB
- Karus Therapeutics Ltd
- KYAN Therapeutics Inc
- Medivir AB
- Merck & Co Inc
- Mycovia Pharmaceuticals Inc
- OnKure Inc
- Oryzon Genomics SA
- Quimatryx SL
- Shuttle Pharmaceuticals Inc
- SK Biopharmaceuticals Co Ltd
- Starwise Therapeutics LLC
- Suzhou GenHouse Pharmaceutical Co Ltd
- Tenaya Therapeutics Inc
- Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles
- ACY-1083 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ACY-738 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ACY-775 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ADV-300 - Drug Profile
- Product Description
- Mechanism Of Action
- AJ-302 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AJ-303 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AVS-100 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- C-1A - Drug Profile
- Product Description
- Mechanism Of Action
- citarinostat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CKD-504 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CKD-506 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CKD-510 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CKD-L - Drug Profile
- Product Description
- Mechanism Of Action
- CS-3003 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CVL-608 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CX-1026 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- EKZ-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- fimepinostat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GH-36 - Drug Profile
- Product Description
- Mechanism Of Action
- HDAC6 - Drug Profile
- Product Description
- Mechanism Of Action
- HSB-510 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- JBI-097 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- JBI-802 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KA-2507 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KAN-0440262 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KYAN-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MPT-0B291 - Drug Profile
- Product Description
- Mechanism Of Action
- MPT-0G211 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Nexturastat A - Drug Profile
- Product Description
- Mechanism Of Action
- QTX-125 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- QTX-153 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- remetinostat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ricolinostat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RTSV-5 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SE-7552 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SKLB-23bb - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit HDAC1 and HDAC6 for Breast Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease Type II A - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit HDAC6 for Melanoma - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Charcot-Marie-Tooth Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit HDAC-6 for Autoimmune Disorders, Charcot-Marie-Tooth Disease and Pancreatic Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit HDAC6 for Alzheimer's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit HDAC6 for Glioblastoma - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit HDAC6 for Immunology and Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit HDAC6 for Rett Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit HDAC6 for Unspecified Indications - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SP-259 - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptides to Inhibit HDAC6 for Solid tumor, Fibrosis and Neurology - Drug Profile
- Product Description
- Mechanism Of Action
- TN-301 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- vorinostat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Products
- Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Product Development Milestones
- Featured News & Press Releases
- Jul 06, 2022: Tenaya Therapeutics publishes preclinical data in science translational medicine detailing discovery of HDAC6 inhibitor for treatment of heart failure
- May 20, 2022: Tenaya Therapeutics to present preclinical data on TN-301 HDAC6 inhibitor at European Society of Cardiology Heart Failure 2022 Conference
- Apr 26, 2022: Jubilant Therapeutics doses first patient in phase I/II trial evaluating JBI-802, dual inhibitor of LSD1 and HDAC6, in patients with advanced solid tumors
- Mar 11, 2022: AnnJi Pharmaceutical’s HDAC6 selective inhibitor received “Grass Roots” support program award sponsored by Boehringer Ingelheim, Taiwan
- Feb 01, 2022: Hillstream BioPharma announces acceptance of abstract at AACR 2022 annual meeting highlighting HSB-510, a novel quatramer-based, first-in-class dual inhibitor of HDAC6 and PI3K-delta downregulating c-myc expression
- Jan 06, 2022: Jubilant Therapeutics announces FDA clearance of IND for JBI-802, a novel dual LSD1 and HDAC6 inhibitor, for treatment of solid tumors
- Nov 18, 2021: Results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published
- Sep 30, 2021: Jubilant Therapeutics announces successful completion of Pre-IND meeting with FDA for its novel dual LSD1 and HDAC6 inhibitor JB1-802
- Aug 16, 2021: Medivir strengthens the business development potential of remetinostat through renegotiated multi-party agreement
- Aug 12, 2021: Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research
- Aug 06, 2021: Medivir: First-in-class histone deacetylase inhibitor gel shows promise for the treatment of patients with basal cell carcinoma
- Jul 29, 2021: Shuttle Pharma awarded a new patent for selective inhibitors for cancer treatment
- Jul 13, 2021: Tenaya Therapeutics unveils preclinical research supporting product candidate for rare and prevalent heart disease indications at ESC Heart Failure 2021
- May 20, 2021: Positive results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published
- Dec 07, 2020: Jubilant Therapeutics announces efficacy and biomarker data at 62nd ASH Annual Meeting for its Novel Dual LSD1-HDAC6 Inhibitor for the Treatment of Hematological Cancers
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Annji Pharmaceutical Co Ltd, 2022
- Pipeline by ATP Biopharm, 2022
- Pipeline by Augustine Therapeutics, 2022
- Pipeline by Avstera Therapeutics Inc, 2022
- Pipeline by Beijing Konruns Pharmaceutical Co Ltd, 2022
- Pipeline by Bristol-Myers Squibb Co, 2022
- Pipeline by Chong Kun Dang Pharmaceutical Corporation, 2022
- Pipeline by Convalife, 2022
- Pipeline by CStone Pharmaceuticals Co Ltd, 2022
- Pipeline by Curis Inc, 2022
- Pipeline by Eikonizo Therapeutics Inc, 2022
- Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2022
- Pipeline by Hillstream BioPharma Inc, 2022
- Pipeline by Jubilant Therapeutics Inc, 2022
- Pipeline by Kancera AB, 2022
- Pipeline by Karus Therapeutics Ltd, 2022
- Pipeline by KYAN Therapeutics Inc, 2022
- Pipeline by Medivir AB, 2022
- Pipeline by Merck & Co Inc, 2022
- Pipeline by Mycovia Pharmaceuticals Inc, 2022
- Pipeline by OnKure Inc, 2022
- Pipeline by Oryzon Genomics SA, 2022
- Pipeline by Quimatryx SL, 2022
- Pipeline by Shuttle Pharmaceuticals Inc, 2022
- Pipeline by SK Biopharmaceuticals Co Ltd, 2022
- Pipeline by Starwise Therapeutics LLC, 2022
- Pipeline by Suzhou GenHouse Pharmaceutical Co Ltd, 2022
- Pipeline by Tenaya Therapeutics Inc, 2022
- Dormant Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Annji Pharmaceutical Co Ltd
- ATP Biopharm
- Augustine Therapeutics
- Avstera Therapeutics Inc
- Beijing Konruns Pharmaceutical Co Ltd
- Bristol-Myers Squibb Co
- Chong Kun Dang Pharmaceutical Corporation
- Convalife
- CStone Pharmaceuticals Co Ltd
- Curis Inc
- Eikonizo Therapeutics Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Hillstream BioPharma Inc
- Jubilant Therapeutics Inc
- Kancera AB
- Karus Therapeutics Ltd
- KYAN Therapeutics Inc
- Medivir AB
- Merck & Co Inc
- Mycovia Pharmaceuticals Inc
- OnKure Inc
- Oryzon Genomics SA
- Quimatryx SL
- Shuttle Pharmaceuticals Inc
- SK Biopharmaceuticals Co Ltd
- Starwise Therapeutics LLC
- Suzhou GenHouse Pharmaceutical Co Ltd
- Tenaya Therapeutics Inc
